Benjamin Rotz

Company: Eli Lilly & Co.

Job title: Associate Vice President, Global Medical Policy Strategy & Operations

Seminars:

Better Understanding the Approach Towards Post-Trial Access 10:30 am

As these programs are expensive to set up and operate, there is a risk to your company if the drug isn’t commercialized. An exit strategy must be clearly defined. Attend this discussion for answers on the following: • What are the options when ending a program in a country where the drugs won’t be commercialized?…Read more

day: Pre-Conference Day Track B 2